Characteristics of hormone therapy, cognitive function, and dementia: The prospective 3C Study
Identifieur interne : 002967 ( PascalFrancis/Corpus ); précédent : 002966; suivant : 002968Characteristics of hormone therapy, cognitive function, and dementia: The prospective 3C Study
Auteurs : J. Ryan ; I. Carriere ; J. Scali ; J. F. Dartigues ; C. Tzourio ; M. Poncet ; K. Ritchie ; M. L. AncelinSource :
- Neurology [ 0028-3878 ] ; 2009.
Descripteurs français
- Pascal (Inist)
English descriptors
Abstract
Objectives: To examine the association between hormone therapy (HT) and cognitive performance or dementia, focusing on the duration and type of treatment used, as well as the timing of initiation of HT in relation to the menopause. Methods: Women 65 years and older were recruited in France as part of the Three City Study. At baseline and 2- and 4-year follow-up, women were administered a short cognitive test battery and a clinical diagnosis of dementia was made. Detailed information was also gathered relating to current and past HT use. Analysis was adjusted for a number of sociodemographic, behavioral, physical, and mental health variables, as well as APOE ∈4. Results: Among 3,130 naturally postmenopausal women, current HT users performed significantly better than never users on verbal fluency, working memory, and psychomotor speed. These associations varied according to the type of treatment and a longer duration of HT appeared to be more beneficial. However, initiation of HT close to the menopause was not associated with better cognition. HT did not significantly reduce dementia risk over 4 years but current treatment diminished the negative effect associated with APOE ∈4. Conclusions: Current hormone therapy (HT) was associated with better performance in certain cognitive domains but these associations are dependent on the duration and type of treatment used. We found no evidence that HT needs to be initiated close to the menopause to have a beneficial effect on cognitive function in later life. Current HT may decrease the risk of dementia associated with the APOE ∈4 allele.
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
| pA |
|
|---|
Format Inist (serveur)
| NO : | PASCAL 10-0019492 INIST |
|---|---|
| ET : | Characteristics of hormone therapy, cognitive function, and dementia: The prospective 3C Study |
| AU : | RYAN (J.); CARRIERE (I.); SCALI (J.); DARTIGUES (J. F.); TZOURIO (C.); PONCET (M.); RITCHIE (K.); ANCELIN (M. L.) |
| AF : | INSERM (J.R., I.C., J.S., K.R., M.L.A.), U888/Montpellier/France (1 aut., 2 aut., 3 aut.); University Montpellier I/Montpellier/France (1 aut., 2 aut., 3 aut., 7 aut., 8 aut.); Department of Psychiatry Q.R.), The University of Melbourne/Melbourne/Australie (1 aut.); INSERM (U.F.D.), U897, University Bordeaux 2/Bordeaux/France (4 aut.); INSERM (C.T.), U708/Paris/France (5 aut.); UPMC University Paris 06/Paris/France (5 aut.); INSERM (M.P.), U751, CHU La Timone/Marseille/France (6 aut.) |
| DT : | Publication en série; Niveau analytique |
| SO : | Neurology; ISSN 0028-3878; Coden NEURAI; Etats-Unis; Da. 2009; Vol. 73; No. 21; Pp. 1729-1737; Bibl. 39 ref. |
| LA : | Anglais |
| EA : | Objectives: To examine the association between hormone therapy (HT) and cognitive performance or dementia, focusing on the duration and type of treatment used, as well as the timing of initiation of HT in relation to the menopause. Methods: Women 65 years and older were recruited in France as part of the Three City Study. At baseline and 2- and 4-year follow-up, women were administered a short cognitive test battery and a clinical diagnosis of dementia was made. Detailed information was also gathered relating to current and past HT use. Analysis was adjusted for a number of sociodemographic, behavioral, physical, and mental health variables, as well as APOE ∈4. Results: Among 3,130 naturally postmenopausal women, current HT users performed significantly better than never users on verbal fluency, working memory, and psychomotor speed. These associations varied according to the type of treatment and a longer duration of HT appeared to be more beneficial. However, initiation of HT close to the menopause was not associated with better cognition. HT did not significantly reduce dementia risk over 4 years but current treatment diminished the negative effect associated with APOE ∈4. Conclusions: Current hormone therapy (HT) was associated with better performance in certain cognitive domains but these associations are dependent on the duration and type of treatment used. We found no evidence that HT needs to be initiated close to the menopause to have a beneficial effect on cognitive function in later life. Current HT may decrease the risk of dementia associated with the APOE ∈4 allele. |
| CC : | 002B17; 002B17G |
| FD : | Démence; Pathologie du système nerveux; Hormone; Thérapie cognitive; Prospective |
| FG : | Maladie dégénérative |
| ED : | Dementia; Nervous system diseases; Hormone; Cognitive therapy; Prospective |
| EG : | Degenerative disease |
| SD : | Demencia; Sistema nervioso patología; Hormona; Terapia cognitiva; Prospectiva |
| LO : | INIST-6345.354000186568930040 |
| ID : | 10-0019492 |
Links to Exploration step
Pascal:10-0019492Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Characteristics of hormone therapy, cognitive function, and dementia: The prospective 3C Study</title><author><name sortKey="Ryan, J" sort="Ryan, J" uniqKey="Ryan J" first="J." last="Ryan">J. Ryan</name><affiliation><inist:fA14 i1="01"><s1>INSERM (J.R., I.C., J.S., K.R., M.L.A.), U888</s1><s2>Montpellier</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="02"><s1>University Montpellier I</s1><s2>Montpellier</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="03"><s1>Department of Psychiatry Q.R.), The University of Melbourne</s1><s2>Melbourne</s2><s3>AUS</s3><sZ>1 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Carriere, I" sort="Carriere, I" uniqKey="Carriere I" first="I." last="Carriere">I. Carriere</name><affiliation><inist:fA14 i1="01"><s1>INSERM (J.R., I.C., J.S., K.R., M.L.A.), U888</s1><s2>Montpellier</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="02"><s1>University Montpellier I</s1><s2>Montpellier</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Scali, J" sort="Scali, J" uniqKey="Scali J" first="J." last="Scali">J. Scali</name><affiliation><inist:fA14 i1="01"><s1>INSERM (J.R., I.C., J.S., K.R., M.L.A.), U888</s1><s2>Montpellier</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="02"><s1>University Montpellier I</s1><s2>Montpellier</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Dartigues, J F" sort="Dartigues, J F" uniqKey="Dartigues J" first="J. F." last="Dartigues">J. F. Dartigues</name><affiliation><inist:fA14 i1="04"><s1>INSERM (U.F.D.), U897, University Bordeaux 2</s1><s2>Bordeaux</s2><s3>FRA</s3><sZ>4 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Tzourio, C" sort="Tzourio, C" uniqKey="Tzourio C" first="C." last="Tzourio">C. Tzourio</name><affiliation><inist:fA14 i1="05"><s1>INSERM (C.T.), U708</s1><s2>Paris</s2><s3>FRA</s3><sZ>5 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="06"><s1>UPMC University Paris 06</s1><s2>Paris</s2><s3>FRA</s3><sZ>5 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Poncet, M" sort="Poncet, M" uniqKey="Poncet M" first="M." last="Poncet">M. Poncet</name><affiliation><inist:fA14 i1="07"><s1>INSERM (M.P.), U751, CHU La Timone</s1><s2>Marseille</s2><s3>FRA</s3><sZ>6 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Ritchie, K" sort="Ritchie, K" uniqKey="Ritchie K" first="K." last="Ritchie">K. Ritchie</name><affiliation><inist:fA14 i1="02"><s1>University Montpellier I</s1><s2>Montpellier</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Ancelin, M L" sort="Ancelin, M L" uniqKey="Ancelin M" first="M. L." last="Ancelin">M. L. Ancelin</name><affiliation><inist:fA14 i1="02"><s1>University Montpellier I</s1><s2>Montpellier</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">10-0019492</idno><date when="2009">2009</date><idno type="stanalyst">PASCAL 10-0019492 INIST</idno><idno type="RBID">Pascal:10-0019492</idno><idno type="wicri:Area/PascalFrancis/Corpus">002967</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Characteristics of hormone therapy, cognitive function, and dementia: The prospective 3C Study</title><author><name sortKey="Ryan, J" sort="Ryan, J" uniqKey="Ryan J" first="J." last="Ryan">J. Ryan</name><affiliation><inist:fA14 i1="01"><s1>INSERM (J.R., I.C., J.S., K.R., M.L.A.), U888</s1><s2>Montpellier</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="02"><s1>University Montpellier I</s1><s2>Montpellier</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="03"><s1>Department of Psychiatry Q.R.), The University of Melbourne</s1><s2>Melbourne</s2><s3>AUS</s3><sZ>1 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Carriere, I" sort="Carriere, I" uniqKey="Carriere I" first="I." last="Carriere">I. Carriere</name><affiliation><inist:fA14 i1="01"><s1>INSERM (J.R., I.C., J.S., K.R., M.L.A.), U888</s1><s2>Montpellier</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="02"><s1>University Montpellier I</s1><s2>Montpellier</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Scali, J" sort="Scali, J" uniqKey="Scali J" first="J." last="Scali">J. Scali</name><affiliation><inist:fA14 i1="01"><s1>INSERM (J.R., I.C., J.S., K.R., M.L.A.), U888</s1><s2>Montpellier</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="02"><s1>University Montpellier I</s1><s2>Montpellier</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Dartigues, J F" sort="Dartigues, J F" uniqKey="Dartigues J" first="J. F." last="Dartigues">J. F. Dartigues</name><affiliation><inist:fA14 i1="04"><s1>INSERM (U.F.D.), U897, University Bordeaux 2</s1><s2>Bordeaux</s2><s3>FRA</s3><sZ>4 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Tzourio, C" sort="Tzourio, C" uniqKey="Tzourio C" first="C." last="Tzourio">C. Tzourio</name><affiliation><inist:fA14 i1="05"><s1>INSERM (C.T.), U708</s1><s2>Paris</s2><s3>FRA</s3><sZ>5 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="06"><s1>UPMC University Paris 06</s1><s2>Paris</s2><s3>FRA</s3><sZ>5 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Poncet, M" sort="Poncet, M" uniqKey="Poncet M" first="M." last="Poncet">M. Poncet</name><affiliation><inist:fA14 i1="07"><s1>INSERM (M.P.), U751, CHU La Timone</s1><s2>Marseille</s2><s3>FRA</s3><sZ>6 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Ritchie, K" sort="Ritchie, K" uniqKey="Ritchie K" first="K." last="Ritchie">K. Ritchie</name><affiliation><inist:fA14 i1="02"><s1>University Montpellier I</s1><s2>Montpellier</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Ancelin, M L" sort="Ancelin, M L" uniqKey="Ancelin M" first="M. L." last="Ancelin">M. L. Ancelin</name><affiliation><inist:fA14 i1="02"><s1>University Montpellier I</s1><s2>Montpellier</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14></affiliation></author></analytic><series><title level="j" type="main">Neurology</title><title level="j" type="abbreviated">Neurology</title><idno type="ISSN">0028-3878</idno><imprint><date when="2009">2009</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Neurology</title><title level="j" type="abbreviated">Neurology</title><idno type="ISSN">0028-3878</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cognitive therapy</term><term>Dementia</term><term>Hormone</term><term>Nervous system diseases</term><term>Prospective</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Démence</term><term>Pathologie du système nerveux</term><term>Hormone</term><term>Thérapie cognitive</term><term>Prospective</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Objectives: To examine the association between hormone therapy (HT) and cognitive performance or dementia, focusing on the duration and type of treatment used, as well as the timing of initiation of HT in relation to the menopause. Methods: Women 65 years and older were recruited in France as part of the Three City Study. At baseline and 2- and 4-year follow-up, women were administered a short cognitive test battery and a clinical diagnosis of dementia was made. Detailed information was also gathered relating to current and past HT use. Analysis was adjusted for a number of sociodemographic, behavioral, physical, and mental health variables, as well as APOE ∈4. Results: Among 3,130 naturally postmenopausal women, current HT users performed significantly better than never users on verbal fluency, working memory, and psychomotor speed. These associations varied according to the type of treatment and a longer duration of HT appeared to be more beneficial. However, initiation of HT close to the menopause was not associated with better cognition. HT did not significantly reduce dementia risk over 4 years but current treatment diminished the negative effect associated with APOE ∈4. Conclusions: Current hormone therapy (HT) was associated with better performance in certain cognitive domains but these associations are dependent on the duration and type of treatment used. We found no evidence that HT needs to be initiated close to the menopause to have a beneficial effect on cognitive function in later life. Current HT may decrease the risk of dementia associated with the APOE ∈4 allele.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0028-3878</s0></fA01><fA02 i1="01"><s0>NEURAI</s0></fA02><fA03 i2="1"><s0>Neurology</s0></fA03><fA05><s2>73</s2></fA05><fA06><s2>21</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Characteristics of hormone therapy, cognitive function, and dementia: The prospective 3C Study</s1></fA08><fA11 i1="01" i2="1"><s1>RYAN (J.)</s1></fA11><fA11 i1="02" i2="1"><s1>CARRIERE (I.)</s1></fA11><fA11 i1="03" i2="1"><s1>SCALI (J.)</s1></fA11><fA11 i1="04" i2="1"><s1>DARTIGUES (J. F.)</s1></fA11><fA11 i1="05" i2="1"><s1>TZOURIO (C.)</s1></fA11><fA11 i1="06" i2="1"><s1>PONCET (M.)</s1></fA11><fA11 i1="07" i2="1"><s1>RITCHIE (K.)</s1></fA11><fA11 i1="08" i2="1"><s1>ANCELIN (M. L.)</s1></fA11><fA14 i1="01"><s1>INSERM (J.R., I.C., J.S., K.R., M.L.A.), U888</s1><s2>Montpellier</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ></fA14><fA14 i1="02"><s1>University Montpellier I</s1><s2>Montpellier</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></fA14><fA14 i1="03"><s1>Department of Psychiatry Q.R.), The University of Melbourne</s1><s2>Melbourne</s2><s3>AUS</s3><sZ>1 aut.</sZ></fA14><fA14 i1="04"><s1>INSERM (U.F.D.), U897, University Bordeaux 2</s1><s2>Bordeaux</s2><s3>FRA</s3><sZ>4 aut.</sZ></fA14><fA14 i1="05"><s1>INSERM (C.T.), U708</s1><s2>Paris</s2><s3>FRA</s3><sZ>5 aut.</sZ></fA14><fA14 i1="06"><s1>UPMC University Paris 06</s1><s2>Paris</s2><s3>FRA</s3><sZ>5 aut.</sZ></fA14><fA14 i1="07"><s1>INSERM (M.P.), U751, CHU La Timone</s1><s2>Marseille</s2><s3>FRA</s3><sZ>6 aut.</sZ></fA14><fA20><s1>1729-1737</s1></fA20><fA21><s1>2009</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>6345</s2><s5>354000186568930040</s5></fA43><fA44><s0>0000</s0><s1>© 2010 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>39 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>10-0019492</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Neurology</s0></fA64><fA66 i1="01"><s0>USA</s0></fA66><fC01 i1="01" l="ENG"><s0>Objectives: To examine the association between hormone therapy (HT) and cognitive performance or dementia, focusing on the duration and type of treatment used, as well as the timing of initiation of HT in relation to the menopause. Methods: Women 65 years and older were recruited in France as part of the Three City Study. At baseline and 2- and 4-year follow-up, women were administered a short cognitive test battery and a clinical diagnosis of dementia was made. Detailed information was also gathered relating to current and past HT use. Analysis was adjusted for a number of sociodemographic, behavioral, physical, and mental health variables, as well as APOE ∈4. Results: Among 3,130 naturally postmenopausal women, current HT users performed significantly better than never users on verbal fluency, working memory, and psychomotor speed. These associations varied according to the type of treatment and a longer duration of HT appeared to be more beneficial. However, initiation of HT close to the menopause was not associated with better cognition. HT did not significantly reduce dementia risk over 4 years but current treatment diminished the negative effect associated with APOE ∈4. Conclusions: Current hormone therapy (HT) was associated with better performance in certain cognitive domains but these associations are dependent on the duration and type of treatment used. We found no evidence that HT needs to be initiated close to the menopause to have a beneficial effect on cognitive function in later life. Current HT may decrease the risk of dementia associated with the APOE ∈4 allele.</s0></fC01><fC02 i1="01" i2="X"><s0>002B17</s0></fC02><fC02 i1="02" i2="X"><s0>002B17G</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Démence</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Dementia</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Demencia</s0><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Pathologie du système nerveux</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Hormone</s0><s5>09</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Hormone</s0><s5>09</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Hormona</s0><s5>09</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Thérapie cognitive</s0><s5>10</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Cognitive therapy</s0><s5>10</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Terapia cognitiva</s0><s5>10</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Prospective</s0><s5>11</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Prospective</s0><s5>11</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Prospectiva</s0><s5>11</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Maladie dégénérative</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Degenerative disease</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0><s5>37</s5></fC07><fN21><s1>011</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard><server><NO>PASCAL 10-0019492 INIST</NO><ET>Characteristics of hormone therapy, cognitive function, and dementia: The prospective 3C Study</ET><AU>RYAN (J.); CARRIERE (I.); SCALI (J.); DARTIGUES (J. F.); TZOURIO (C.); PONCET (M.); RITCHIE (K.); ANCELIN (M. L.)</AU><AF>INSERM (J.R., I.C., J.S., K.R., M.L.A.), U888/Montpellier/France (1 aut., 2 aut., 3 aut.); University Montpellier I/Montpellier/France (1 aut., 2 aut., 3 aut., 7 aut., 8 aut.); Department of Psychiatry Q.R.), The University of Melbourne/Melbourne/Australie (1 aut.); INSERM (U.F.D.), U897, University Bordeaux 2/Bordeaux/France (4 aut.); INSERM (C.T.), U708/Paris/France (5 aut.); UPMC University Paris 06/Paris/France (5 aut.); INSERM (M.P.), U751, CHU La Timone/Marseille/France (6 aut.)</AF><DT>Publication en série; Niveau analytique</DT><SO>Neurology; ISSN 0028-3878; Coden NEURAI; Etats-Unis; Da. 2009; Vol. 73; No. 21; Pp. 1729-1737; Bibl. 39 ref.</SO><LA>Anglais</LA><EA>Objectives: To examine the association between hormone therapy (HT) and cognitive performance or dementia, focusing on the duration and type of treatment used, as well as the timing of initiation of HT in relation to the menopause. Methods: Women 65 years and older were recruited in France as part of the Three City Study. At baseline and 2- and 4-year follow-up, women were administered a short cognitive test battery and a clinical diagnosis of dementia was made. Detailed information was also gathered relating to current and past HT use. Analysis was adjusted for a number of sociodemographic, behavioral, physical, and mental health variables, as well as APOE ∈4. Results: Among 3,130 naturally postmenopausal women, current HT users performed significantly better than never users on verbal fluency, working memory, and psychomotor speed. These associations varied according to the type of treatment and a longer duration of HT appeared to be more beneficial. However, initiation of HT close to the menopause was not associated with better cognition. HT did not significantly reduce dementia risk over 4 years but current treatment diminished the negative effect associated with APOE ∈4. Conclusions: Current hormone therapy (HT) was associated with better performance in certain cognitive domains but these associations are dependent on the duration and type of treatment used. We found no evidence that HT needs to be initiated close to the menopause to have a beneficial effect on cognitive function in later life. Current HT may decrease the risk of dementia associated with the APOE ∈4 allele.</EA><CC>002B17; 002B17G</CC><FD>Démence; Pathologie du système nerveux; Hormone; Thérapie cognitive; Prospective</FD><FG>Maladie dégénérative</FG><ED>Dementia; Nervous system diseases; Hormone; Cognitive therapy; Prospective</ED><EG>Degenerative disease</EG><SD>Demencia; Sistema nervioso patología; Hormona; Terapia cognitiva; Prospectiva</SD><LO>INIST-6345.354000186568930040</LO><ID>10-0019492</ID></server></inist></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002967 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 002967 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PascalFrancis
|étape= Corpus
|type= RBID
|clé= Pascal:10-0019492
|texte= Characteristics of hormone therapy, cognitive function, and dementia: The prospective 3C Study
}}
| This area was generated with Dilib version V0.6.33. |  |